Market closed
Soleno Therapeutics/$SLNO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Soleno Therapeutics
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
Ticker
$SLNO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
33
Website
SLNO Metrics
BasicAdvanced
$2B
Market cap
-
P/E ratio
-$3.47
EPS
-1.44
Beta
-
Dividend rate
Price and volume
Market cap
$2B
Beta
-1.44
52-week high
$60.92
52-week low
$35.04
Average daily volume
630K
Financial strength
Current ratio
17.257
Quick ratio
17.162
Long term debt to equity
0.975
Total debt to equity
1.144
Management effectiveness
Return on assets (TTM)
-48.05%
Return on equity (TTM)
-91.11%
Valuation
Price to book
7.31
Price to tangible book (TTM)
7.52
Price to free cash flow (TTM)
-34.579
Growth
Earnings per share change (TTM)
6.49%
3-year earnings per share growth (CAGR)
-15.86%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Soleno Therapeutics stock?
Soleno Therapeutics (SLNO) has a market cap of $2B as of December 13, 2024.
What is the P/E ratio for Soleno Therapeutics stock?
The price to earnings (P/E) ratio for Soleno Therapeutics (SLNO) stock is 0 as of December 13, 2024.
Does Soleno Therapeutics stock pay dividends?
No, Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders as of December 13, 2024.
When is the next Soleno Therapeutics dividend payment date?
Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders.
What is the beta indicator for Soleno Therapeutics?
Soleno Therapeutics (SLNO) has a beta rating of -1.44. This means that it has an inverse relation to market volatility.